[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,747,441
  • Shares Outstanding, K 73,023
  • Annual Sales, $ 105,970 K
  • Annual Income, $ -81,130 K
  • EBIT $ -114 M
  • EBITDA $ -103 M
  • 60-Month Beta 1.20
  • Price/Sales 16.51
  • Price/Cash Flow N/A
  • Price/Book 10.80

Options Overview Details

View History
  • Implied Volatility 65.89% (+1.16%)
  • Historical Volatility 46.08%
  • IV Percentile 9%
  • IV Rank 10.63%
  • IV High 220.79% on 11/14/25
  • IV Low 47.46% on 08/22/25
  • Expected Move (DTE 33) 3.51 (14.67%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 60
  • Volume Avg (30-Day) 147
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 5,274
  • Open Int (30-Day) 4,216
  • Expected Range 20.42 to 27.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 6
  • High Estimate $0.03
  • Low Estimate $-0.58
  • Prior Year $0.03
  • Growth Rate Est. (year over year) -1,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.39 +2.31%
on 05/08/26
29.75 -19.56%
on 04/27/26
-3.80 (-13.70%)
since 04/15/26
3-Month
21.93 +9.12%
on 02/23/26
29.75 -19.56%
on 04/27/26
+1.33 (+5.88%)
since 02/13/26
52-Week
11.02 +117.15%
on 05/30/25
29.75 -19.56%
on 04/27/26
+12.40 (+107.55%)
since 05/15/25

Most Recent Stories

More News
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...

ZYME : 23.93 (-0.13%)
Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...

ZYME : 23.93 (-0.13%)
Zymeworks Q1 Earnings Call Highlights

Zymeworks (NASDAQ:ZYME) reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across...

ZYME : 23.93 (-0.13%)
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal...

ZYME : 23.93 (-0.13%)
Can Zymeworks Justify Its Valuation Without Commercial Revenue?

Barchart Research What to Expect from ZYME Earnings ZYME Generated May 6, 2026 Current Price $27.61 EPS Estimate $$-0.10 Consensus Rating Strong Buy Average Move 3.55% Can Zymeworks Justify Its Valuation...

ZYME : 23.93 (-0.13%)
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression Confirmed objective response rate (cORR) of 61% at doses 6.4-9.6...

ZYME : 23.93 (-0.13%)
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs  Data highlight efficacy, tumor-selective delivery, and favorable...

ZYME : 23.93 (-0.13%)
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline...

ZYME : 23.93 (-0.13%)
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D • Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc....

ZYME : 23.93 (-0.13%)
Zymeworks Appoints Kristin Stafford as Chief Financial Officer

VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline...

ZYME : 23.93 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 26.67
2nd Resistance Point 26.01
1st Resistance Point 24.97
Last Price 23.93
1st Support Level 23.26
2nd Support Level 22.60
3rd Support Level 21.56

See More

52-Week High 29.75
Last Price 23.93
Fibonacci 61.8% 22.60
Fibonacci 50% 20.39
Fibonacci 38.2% 18.17
52-Week Low 11.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.